Evidence map›Paper›PMID 40788193›Full record

ArticlePain management2025

Opioid reduction in patients with chronic non-cancer pain undergoing treatment with medicinal cannabis.

Philip M Finch, Leanne M Price, Toby J F Price, Michael J Kent, Peter D Drummond

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pain management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Philip M FinchMedika Health, Perth, Australia.ORCID 0000-0002-2717-054X
Leanne M PriceRegistered Nurse, Perth Pain Management Centre, Perth, Australia.
Toby J F PriceWA Country Health Service, Albany, Australia.ORCID 0000-0002-4668-6920
Michael J KentSt John of God hospital, Perth, Australia.
Peter D DrummondSchool of Psychology, Murdoch University, Perth, Western Australia, Australia.ORCID 0000-0002-3711-8737

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOpioid sparing by co-prescription of cannabinoids may enable patients to reduce their opioid consumption prescribed for chronic benign pain.

methodsOne cohort attending a small private pain clinic (

resultsAt baseline, median opioid consumption was 40 mg/day in both cohorts. Medicinal cannabis was administered daily in an oil formulation usually starting at 2.5 mg/day and was titrated to maximize benefits. At 12 months, the median dose contained 15 mg delta-9-tetrahydrocannabinol and 15 mg cannabidiol. At one-year follow-up, 46 of 102 cases had dropped out compared with only one of 53 controls. Opioid consumption had decreased significantly at one-year follow-up, the final median dose being lower in cases (2.7 mg/day) than controls (42.3 mg/day) (

conclusionThe introduction of cannabinoids can produce useful reductions in opioid consumption in real-world settings, with additional benefits for disability and insomnia. However, this treatment is tolerated by only a subgroup of patients. CLINICAL AUDIT REGISTRATION: https://www.anzctr.org.au/ identifier is ACTRN12621000875808.

Indexed as

Analgesics, OpioidChronic PainMedical MarijuanaAdultAgedCannabidiolFemaleHumansMaleMiddle AgedProspective StudiesAnalgesics, OpioidCannabidiolMedical Marijuanaaddiction medicinecannabinoidsclinical auditOpioidsopioid sparingreal world study

Identifiers

PMID40788193
PMCPMC12490380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.